Kawasaki Yumena, Winger Sara, Esteghamat Naseem, Rosenberg Aaron, Beechinor Ryan
Department of Pharmacy, University of California Davis Medical Center, Sacramento, CA, USA.
Comprehensive Cancer Center, Division of Malignant Hematology, Cellular Therapy & Transplantation, University of California Davis Medical Center, Sacramento, CA, USA.
Expert Rev Anticancer Ther. 2024 Dec;24(12):1209-1219. doi: 10.1080/14737140.2024.2445145. Epub 2025 Jan 12.
The rise of recent novel therapies teclistamab, elranatamab, and talquetamab for the treatment of relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area with significant clinical implications that require exploration and evaluation.
The current review highlights the clinical trial data, safety endpoints, and practical administration considerations for the bispecific therapies currently used in multiple myeloma. This article reviewed the efficacy and safety results between the three different bispecifics, and the differences in dosing and monitoring requirements. Adverse event management for the bispecific antibodies will be explored including the need for antimicrobial prophylaxis, premedication, and IVIG replacement. Future considerations for widespread bispecific administration and ongoing clinical trials are discussed.
Practical considerations for bispecific administration such as hospitalization requirements, monitoring of adverse events, and medication considerations are emphasized. Future directions and clinical implications regarding the pivotal role of these agents will be discussed.
用于治疗复发/难治性多发性骨髓瘤（RRMM）的新型疗法——替西妥单抗、埃拉纳妥单抗和他喹妥单抗的兴起是一个快速发展的领域，具有重大临床意义，需要进行探索和评估。
当前综述重点介绍了目前用于多发性骨髓瘤的双特异性疗法的临床试验数据、安全性终点以及实际给药注意事项。本文回顾了三种不同双特异性疗法之间的疗效和安全性结果，以及给药和监测要求的差异。将探讨双特异性抗体的不良事件管理，包括抗菌预防需求、预处理和静脉注射免疫球蛋白替代。还讨论了双特异性药物广泛应用的未来考量以及正在进行的临床试验。
强调了双特异性药物给药的实际考量，如住院要求、不良事件监测和药物考量。将讨论这些药物关键作用的未来方向和临床意义。
